Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ: ARQT · Delayed Price · USD
14.38
-0.70 (-4.64%)
At close: Jan 27, 2022 4:00 PM
20.47
6.09 (42.35%)
After-hours:Jan 27, 2022 5:58 PM EST
Market Cap723.25M
Revenue (ttm)n/a
Net Income (ttm)-169.08M
Shares Out50.30M
EPS (ttm)-3.55
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume203,928
Open15.15
Previous Close15.08
Day's Range14.21 - 15.48
52-Week Range14.16 - 38.49
Betan/a
AnalystsStrong Buy
Price Target53.43 (+271.6%)
Earnings DateFeb 14, 2022

About ARQT

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ...

IndustryBiotechnology
IPO DateJan 31, 2020
Employees143
Stock ExchangeNASDAQ
Ticker SymbolARQT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for ARQT stock is "Strong Buy." The 12-month stock price forecast is 53.43, which is an increase of 271.56% from the latest price.

Price Target
$53.43
(271.56% upside)
Analyst Consensus: Strong Buy

News

Arcutis Secures $225M Debt Financing To Fund Potential Launch Of Roflumilast

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) has obtained a $225 million term loan facility from SLR Capital Partners (SLR).  This additional capital further strengthens Arcutis' balance sheet before a po...

1 month ago - Benzinga

Arcutis Biotherapeutics Secures $225 Million in Non-Dilutive Debt Financing from SLR Capital Partners

WESTLAKE VILLAGE, Calif., Dec. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-d...

1 month ago - GlobeNewsWire

FDA Accepts Arcutis Biotherapeutics' New Drug Application for Roflumilast Cream for Adults and Adolescents with Plaqu...

WESTLAKE VILLAGE, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-d...

1 month ago - GlobeNewsWire

Arcutis Appoints Mas Matsuda as General Counsel and Corporate Secretary

WESTLAKE VILLAGE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-d...

1 month ago - GlobeNewsWire

Arcutis Announces Data Comparing the Vehicle in Investigational Roflumilast Cream Against a Commercial Ceramide-Conta...

WESTLAKE VILLAGE, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-d...

1 month ago - GlobeNewsWire

Arcutis to Present at Upcoming Investor Conference

WESTLAKE VILLAGE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-d...

2 months ago - GlobeNewsWire

Arcutis Announces Third Quarter 2021 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-de...

2 months ago - GlobeNewsWire

New Data Highlighting Itch Reduction with Topical Roflumilast in Multiple Dermatologic Conditions Presented at Europe...

WESTLAKE VILLAGE, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) --   Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immun...

3 months ago - GlobeNewsWire

Arcutis Expands Patent Portfolio with Roflumilast Pharmacokinetics Patent

WESTLAKE VILLAGE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-...

3 months ago - GlobeNewsWire

New Topical Roflumilast Data Presented at the European Academy of Dermatology and Venereology (EADV) Congress

WESTLAKE VILLAGE, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-...

4 months ago - GlobeNewsWire

Is Now the Time to Bet on Arcutis Biotherapeutics?

Management has high hopes for the company's treatment candidates for dermatological conditions, but can they get one to market before its cash cushion is depleted?

4 months ago - The Motley Fool

Arcutis to Present at Upcoming Investor Conferences

WESTLAKE VILLAGE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations in immuno-...

4 months ago - GlobeNewsWire

Arcutis Announces Appointment of Keith Leonard to Board of Directors

WESTLAKE VILLAGE, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address...

4 months ago - GlobeNewsWire

Bruce Binkowitz Joins Arcutis as Vice President of Biometrics

WESTLAKE VILLAGE, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address t...

5 months ago - GlobeNewsWire

Arcutis Announces Second Quarter 2021 Financial Results and Provides Business Update

WESTLAKE VILLAGE, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address t...

5 months ago - GlobeNewsWire

Arcutis Announces Additions to its Investor Relations and Communications Team

WESTLAKE VILLAGE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address ...

5 months ago - GlobeNewsWire

All You Need to Know About Arcutis Biotherapeutics, Inc. (ARQT) Rating Upgrade to Buy

Arcutis Biotherapeutics, Inc. (ARQT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6 months ago - Zacks Investment Research

Arcutis Advances Science of Psoriasis Drug Development with New Precision Method for Measuring Mild-to-Moderate Psori...

WESTLAKE VILLAGE, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- In order to address a major limitation of today's most widely used method for gauging severity of plaque psoriasis (the PASI scale), Arcutis B...

6 months ago - GlobeNewsWire

Arcutis Announces First Patient Enrolled in Phase 3 Clinical Trial of Topical Roflumilast Foam (ARQ-154) as a Potenti...

WESTLAKE VILLAGE, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing meaningful innovations to address t...

6 months ago - GlobeNewsWire

Arcutis (ARQT) Terminates Study of Drug to Treat Vitiligo

Arcutis (ARQT) ends phase IIa study evaluating its investigational anti-JAK1 candidate, ARQ-252, to treat vitiligo.

6 months ago - Zacks Investment Research

Arcutis Stops ARQ-252 Vitiligo Trial After Formulation-Related Observations In Chronic Hand Eczema Study

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) will terminate the Phase 2a trial evaluating ARQ-252 as a potential treatment for vitiligo.  The study was initiated in March 2021.

6 months ago - Benzinga

Arcutis Provides Update on Phase 2a Clinical Trial Evaluating ARQ-252 Cream as a Potential Treatment for Vitiligo

WESTLAKE VILLAGE, Calif., July 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), today announced its decision to terminate the recently initiated Phase 2a clinical trial evalua...

6 months ago - GlobeNewsWire

Greg Sukay Joins Arcutis as Vice President of Manufacturing and Process Technologies

WESTLAKE VILLAGE, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

7 months ago - GlobeNewsWire

Arcutis Announces Appointment of Sue-Jean Lin to Board of Directors

WESTLAKE VILLAGE, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc.  (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for...

7 months ago - GlobeNewsWire

Rajvir Madan Joins Arcutis as Chief Digital and Information Officer

WESTLAKE VILLAGE, Calif., June 01, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for ...

7 months ago - GlobeNewsWire